TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37622035

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 mg on day 1, 100 mg twice daily thereafter for 15 days)
Number of subjects: 547

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 547
Study: 37622180

Group type: EXPERIMENTAL
Intervention: Folic acid and vitamin B12 supplementation
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: MTHFR gene mutations (C677T and A1298C)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: MTHFR C677T polymorphism
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: MTHFR A1298C polymorphism
Number of subjects: 102
Study: 37622641

Group type: EXPERIMENTAL
Intervention: Operative management
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Non-operative management
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Duration of surgery
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Time to re-introduction of normal diet
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Length of hospital stay
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: 30-day mortality rates
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: 90-day mortality rates
Number of subjects: 316
Study: 37622649

Group type: EXPERIMENTAL
Intervention: Parent-reported weight
Number of subjects: 4262

Group type: EXPERIMENTAL
Intervention: Parent-reported length
Number of subjects: 4262

Group type: EXPERIMENTAL
Intervention: Parent-reported BMI
Number of subjects: 4262

Group type: EXPERIMENTAL
Intervention: Categorisation of BMI z-score
Number of subjects: 4262
Study: 37622677

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 2536

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2536

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2536
Study: 37622681

Group type: EXPERIMENTAL
Intervention: Semaglutide (2.4 mg)
Number of subjects: 529

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 529
Study: 37622738

Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin 2.5 mg/kg every 3 weeks
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin 3.4 mg/kg every 3 weeks
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin (both doses)
Number of subjects: 223
Study: 37622754

Group type: EXPERIMENTAL
Intervention: Measured PPM (moderate: 0.65-0.85 or 0.55-0.70 cm)
Number of subjects: 2463

Group type: EXPERIMENTAL
Intervention: Predicted PPM
Number of subjects: 2463

Group type: EXPERIMENTAL
Intervention: Patients with PPM
Number of subjects: 2463
Study: 37623000

Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with parents regarding perceptions of cancer
Number of subjects: 45
Study: 37623007

Group type: EXPERIMENTAL
Intervention: Combination of 24 months of ADT, PBRT, and PLNRT
Number of subjects: 46
Study: 37623189

Group type: EXPERIMENTAL
Intervention: Waist-to-height ratio
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Finnish Diabetes Risk instrument
Number of subjects: 220
Study: 37623203

Group type: EXPERIMENTAL
Intervention: Green coconut water (330 mL)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Dark chocolate (35 g of 70% dark chocolate)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg)
Number of subjects: 45
Study: 37623205

Group type: EXPERIMENTAL
Intervention: Intensive behavioral treatment intervention (IC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (CC)
Number of subjects: 0
Study: 37623329

Group type: EXPERIMENTAL
Intervention: 0.05 mmol/kg gadobutrol (half dose)
Number of subjects: 25

Group type: COMPARATOR
Intervention: 0.1 mmol/kg gadobutrol (single dose)
Number of subjects: 25
Study: 37623428

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 519

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study: 37624364

Group type: EXPERIMENTAL
Intervention: Biodegradable-polymer sirolimus-eluting stents
Number of subjects: 1948

Group type: COMPARATOR
Intervention: Durable-polymer zotarolimus-eluting stents
Number of subjects: 1948
Study: 37624376

Group type: EXPERIMENTAL
Intervention: Mycoprotein
Number of subjects: 20
Study: 37624389

Group type: EXPERIMENTAL
Intervention: Isometric ballistic and peak torque during maximal voluntary contractions (pkT)
Number of subjects: 70
Study: 37624421

Group type: EXPERIMENTAL
Intervention: Alpelisib
Number of subjects: 37
Study: 37624488

Group type: EXPERIMENTAL
Intervention: Abrocitinib
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study: 37624605

Group type: EXPERIMENTAL
Intervention: Visual Field Modeling and Analysis (VFMA)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Mean Sensitivity (MS)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Hill-of-vision (HOV) derived metric of VTOT
Number of subjects: 189

Group type: COMPARATOR
Intervention: Open-source implementation (OSI)
Number of subjects: 189
Study: 37624619

Group type: EXPERIMENTAL
Intervention: Pirtobrutinib monotherapy (200 mg once daily)
Number of subjects: 120
Study: 37624622

Group type: EXPERIMENTAL
Intervention: EPIO intervention (n=132)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Care-as-usual control group (n=134)
Number of subjects: 266
Study: 37624707

Group type: EXPERIMENTAL
Intervention: Self-paced pattern recognition training using a large-scale interactive image repository (LIIR) through a quiz-based smartphone app.
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Self-paced pattern recognition training using a LIIR with patient cases delivered by a quiz-based mobile app.
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Self-paced pattern recognition training using a LIIR.
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (no training).
Number of subjects: 115
Study: 37624739

Group type: EXPERIMENTAL
Intervention: AAVrh.10hCLN2 administered via intracisternal delivery to cerebrospinal fluid (CSF)
Number of subjects: 0
Study: 37624900

Group type: EXPERIMENTAL
Intervention: Graded Exposure Treatment (GET Living)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Multidisciplinary Pain Management (MPM)
Number of subjects: 68
Study: 37624901

Group type: EXPERIMENTAL
Intervention: Usual care plus intervention (pain coping skills training and optional support for opioid taper)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 153
Study: 37625011

Group type: EXPERIMENTAL
Intervention: Innovative, nurse-co-ordinated, multi-faceted intervention to lower rehospitalization and death by addressing areas of vulnerability to external challenges to health.
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Innovative, nurse-co-ordinated, multi-faceted intervention
Number of subjects: 203
Study: 37625034

Group type: EXPERIMENTAL
Intervention: Cannabis use for medical symptoms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37625088

Group type: EXPERIMENTAL
Intervention: DARE-HRT1 IVR1 (E2 80 μg/d with P4 4 mg/d)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: DARE-HRT1 IVR2 (E2 160 μg/d with P4 8 mg/d)
Number of subjects: 21
Study: 37625110

Group type: EXPERIMENTAL
Intervention: Usual care augmented with a trained community health worker (CHW) for 12 months
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 160
Study: 37625235

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg every 3 weeks for 22 cycles with platinum-based chemotherapy and bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with platinum-based chemotherapy and bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atezolizumab and placebo
Number of subjects: 0
Study: 37625386

Group type: EXPERIMENTAL
Intervention: 2-month ambulatory supervised aerobic exercise program (aEP) followed by 6-month home-based aEP with heart rate targeting using ECG
Number of subjects: 132

Group type: COMPARATOR
Intervention: 2-month ambulatory supervised aerobic exercise program (aEP) followed by 6-month home-based aEP without heart rate targeting
Number of subjects: 132
Study: 37625408

Group type: EXPERIMENTAL
Intervention: Non-dysplastic Lugol unstaining lesions (ND-LULs)
Number of subjects: 163
Study: 37625434

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01
Number of subjects: 5098

Group type: COMPARATOR
Intervention: SMC alone
Number of subjects: 5098
Study: 37625498

Group type: EXPERIMENTAL
Intervention: Post-radiotherapy LARS prediction model (PORTLARS)
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: PORTLARS
Number of subjects: 868
Study: 37625518

Group type: EXPERIMENTAL
Intervention: 250 mg JNJ-10450232 (NTM-006)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1000 mg JNJ-10450232 (NTM-006)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1000 mg acetaminophen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37625526

Group type: EXPERIMENTAL
Intervention: Highest quartile of HOMA-IR (indicating higher insulin resistance)
Number of subjects: 2754
Study: 37625587

Group type: EXPERIMENTAL
Intervention: High dose esomeprazole (80 mg bolus followed by 12 mg/h for 72 h and a second 80 mg bolus 12 h after the first one)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Equivolume placebo (sodium chloride 0.9%)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: High dose esomeprazole
Number of subjects: 300
Study: 37625684

Group type: EXPERIMENTAL
Intervention: Family Foundations program (9-session perinatal preventative intervention)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 366
Study: 37625814

Group type: EXPERIMENTAL
Intervention: TQB2450 (1200 mg every 3 weeks) and anlotinib (10 mg or 12 mg once daily, 2-week on/1-week off)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: TQB2450 and anlotinib
Number of subjects: 19
Study: 37626074

Group type: EXPERIMENTAL
Intervention: Active anodal tDCS over the occipital lobe for 28 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham anodal tDCS over the occipital lobe for 28 days
Number of subjects: 0
Study: 37626137

Group type: EXPERIMENTAL
Intervention: Gana V
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sculptra
Number of subjects: 55
Study: 37626170

Group type: EXPERIMENTAL
Intervention: ARO-ANG3
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 37626292

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 315

Group type: COMPARATOR
Intervention: Control (oxytocin alone)
Number of subjects: 315
Study: 37626303

Group type: EXPERIMENTAL
Intervention: Sugammadex (2 mg/kg)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control group (saline infusion)
Number of subjects: 171
Study: 37626312

Group type: EXPERIMENTAL
Intervention: Housing modifications (screening windows, doors, ceilings, insecticide-impregnated materials)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Housing modifications
Number of subjects: 24
Study: 37626349

Group type: EXPERIMENTAL
Intervention: Preoperative attachment anxiety and avoidance
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Self-esteem and health self-efficacy
Number of subjects: 263
Study: 37626367

Group type: EXPERIMENTAL
Intervention: Camrelizumab combined with radiotherapy as neoadjuvant therapy
Number of subjects: 25
Study: 37626387

Group type: EXPERIMENTAL
Intervention: HAMS-AB (high amylose maize starch - acetylated and butyrylated form)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HAMS-AB
Number of subjects: 12
Study: 37626416

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cells (auto-BM-MNC)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Allogeneic Wharton jelly-derived mesenchymal stem cells (allo-WJ-MSCs)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 24
Study: 37626422

Group type: EXPERIMENTAL
Intervention: Positive Behavior Management Implementation Resources (PBMIR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No additional implementation support (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PBMIR
Number of subjects: 0
Study: 37626428

Group type: EXPERIMENTAL
Intervention: Technology-assisted peer-delivered Thinking Healthy Programme (THP)
Number of subjects: 980

Group type: COMPARATOR
Intervention: Standard face-to-face Thinking Healthy Programme delivered by trained health workers
Number of subjects: 980
Study: 37626477

Group type: EXPERIMENTAL
Intervention: Evobrutinib
Number of subjects: 45
Study: 37628548

Group type: EXPERIMENTAL
Intervention: Slow Breathing Method 1 (SB1)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Slow Breathing Method 2 (SB2)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Normal Breathing (Control)
Number of subjects: 79
Study: 37629234

Group type: EXPERIMENTAL
Intervention: Dizziness Handicap Inventory at one year post-injury
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Demographic and injury-related variables, clinical findings, and measures of post-injury symptoms and functioning
Number of subjects: 64
Study: 37629318

Group type: EXPERIMENTAL
Intervention: Walk advice (WA) with Nordic pole walking
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Home-based structured exercise programs (HSEP)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Supervised exercise (SEP)
Number of subjects: 149
Study: 37629366

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 239

Group type: COMPARATOR
Intervention: No-CPAP treatment (control)
Number of subjects: 239
Study: 37629638

Group type: EXPERIMENTAL
Intervention: Topical application of a class I pullulan-based medical device, applied two times daily.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract).
Number of subjects: 64
Study: 37629671

Group type: EXPERIMENTAL
Intervention: Intramuscular Electrical Stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37631885

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen (two doses with a 56-day interval)
Number of subjects: 0
Study: 37632201

Group type: EXPERIMENTAL
Intervention: Zibotentan 0.25 mg/dapagliflozin 10 mg QD
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Zibotentan 1.5 mg/dapagliflozin 10 mg QD
Number of subjects: 447

Group type: COMPARATOR
Intervention: Dapagliflozin 10 mg QD alone
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 447
Study: 37632240

Group type: EXPERIMENTAL
Intervention: Epinephrine/adrenaline injection
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Consultation with an allergist
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Auto-injector prescription
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Guidelines-based management factors
Number of subjects: 1056
Study: 37632249

Group type: EXPERIMENTAL
Intervention: Follicular flushing
Number of subjects: 105

Group type: COMPARATOR
Intervention: Single aspiration
Number of subjects: 105
Study: 37632341

Group type: EXPERIMENTAL
Intervention: Transition intervention components (up to five components over 3 months)
Number of subjects: 31
Study: 37632455

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 6250

Group type: COMPARATOR
Intervention: Outpatient oral diuretic intensification
Number of subjects: 6250

Group type: COMPARATOR
Intervention: HF hospitalization
Number of subjects: 6250

Group type: COMPARATOR
Intervention: Expanded composite end point (cardiovascular death, HF hospitalization, urgent HF visit, or outpatient oral diuretic intensification)
Number of subjects: 6250
Study: 37632452

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (NIVO + IPI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pembrolizumab plus axitinib (PEM + AXI)
Number of subjects: 0
Study: 37632469

Group type: EXPERIMENTAL
Intervention: Alirocumab (PCSK9 inhibitor)
Number of subjects: 11970

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11970
Study: 37632463

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Number of subjects: 3065

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3065
Study: 37632466

Group type: EXPERIMENTAL
Intervention: Five modifiable risk factors (body-mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking, diabetes)
Number of subjects: 1518028
Study: 37632493

Group type: EXPERIMENTAL
Intervention: CF-LVAD implantation (Visit 1 before implantation)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CF-LVAD implantation (Visit 2 after implantation with pump speed held constant)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CF-LVAD implantation (Visit 3 with increased pump speed during exercise)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Preimplantation testing
Number of subjects: 10
Study: 37632515

Group type: EXPERIMENTAL
Intervention: Differential target multiplexed spinal cord stimulation (SCS) with increased stimulation amplitude to a maximum tolerable value
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Differential target multiplexed spinal cord stimulation (SCS)
Number of subjects: 24
Study: 37632592

Group type: EXPERIMENTAL
Intervention: Carfilzomib (10, 15, or 20 mg/m2) in combination with R-ICE (rituximab, ifosfamide, carboplatin, etoposide)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Carfilzomib
Number of subjects: 28
Study: 37632656

Group type: EXPERIMENTAL
Intervention: 24-hour/day foslevodopa/foscarbidopa CSCI at individually optimized therapeutic doses (approximately 700-4250 mg of LD per 24 hours)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: 24-hour/day foslevodopa/foscarbidopa CSCI
Number of subjects: 244
Study: 37632666

Group type: EXPERIMENTAL
Intervention: SB5 biosimilar adalimumab
Number of subjects: 955
Study: 37632909

Group type: EXPERIMENTAL
Intervention: Inorganic sunscreen (SPF 30)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Organic sunscreen (SPF 30)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comparison of inorganic vs organic sunscreen after swimming
Number of subjects: 22
Study: 37632942

Group type: EXPERIMENTAL
Intervention: ASICA intervention (digital health care intervention providing monthly prompts for TSSE and access to a dermatology nurse)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 22
Study: 37632976

Group type: EXPERIMENTAL
Intervention: Patient-led surveillance (skin self-examination with patient-performed teledermoscopy)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 100
Study: 37632977

Group type: EXPERIMENTAL
Intervention: eSkinHealth app
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 24
Study: 37633156

Group type: EXPERIMENTAL
Intervention: Venetoclax 100 mg daily from days 1-21, Itraconazole 100 mg twice daily from days 1-21, Azacitidine 100 mg subcutaneously once daily from days 1-7
Number of subjects: 15
Study: 37633159

Group type: EXPERIMENTAL
Intervention: High Definition-tDCS (direct current)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 Hz HD-tACS (alternating current)
Number of subjects: 0
Study: 37633255

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Non-surgical controls (NS)
Number of subjects: 53
Study: 37633275

Group type: EXPERIMENTAL
Intervention: MRG-001
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intermediate MRG-001 dose
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 37633306

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Number of subjects: 543

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 543
Study: 37633331

Group type: EXPERIMENTAL
Intervention: Biofortified whole wheat flour (BFW)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Postharvest fortified wheat (PHFW)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Control wheat (CW)
Number of subjects: 273
Study: 37633572

Group type: EXPERIMENTAL
Intervention: 8-week internet-delivered CBT intervention
Number of subjects: 85
Study: 37633576

Group type: EXPERIMENTAL
Intervention: Mohs-guided excision
Number of subjects: 87

Group type: COMPARATOR
Intervention: Traditional excision
Number of subjects: 87
Study: 37633589

Group type: EXPERIMENTAL
Intervention: LNG 52 mg IUD
Number of subjects: 39

Group type: COMPARATOR
Intervention: CuT380 IUD
Number of subjects: 39
Study: 37633858

Group type: EXPERIMENTAL
Intervention: Father-reported parenting
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Adolescent-reported parenting
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Discrepancies between father and adolescent perceptions
Number of subjects: 326
Study: 37633900

Group type: EXPERIMENTAL
Intervention: LIMK1 hemideletion and haplotype variation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: LIMK1 variation
Number of subjects: 33
Study: 37633916

Group type: EXPERIMENTAL
Intervention: 6-week VR experience program
Number of subjects: 216

Group type: COMPARATOR
Intervention: Usual care provided by the LTCF
Number of subjects: 216
Study: 37633944

Group type: EXPERIMENTAL
Intervention: Out-of-hospital cardiac arrest (OHCA) survivors
Number of subjects: 108
Study: 37634022

Group type: EXPERIMENTAL
Intervention: Acute inflammatory demyelinating polyneuropathy (AIDP)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Acute axonal GBS
Number of subjects: 62
Study: 37634058

Group type: EXPERIMENTAL
Intervention: ACR 2011 criteria
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: ACR 2016 criteria
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: FS scale with cutoff value 11 points
Number of subjects: 200
Study: 37634087

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 6261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6261
Study: 37634089

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone supplementation for 7 days prior to the second questionnaire.
Number of subjects: 286

Group type: COMPARATOR
Intervention: Non-progesterone group (control).
Number of subjects: 286
Study: 37634092

Group type: EXPERIMENTAL
Intervention: OCT-guided PCI
Number of subjects: 2008

Group type: COMPARATOR
Intervention: IVUS-guided PCI
Number of subjects: 2008
Study: 37634128

Group type: EXPERIMENTAL
Intervention: Alpelisib
Number of subjects: 57
Study: 37634135

Group type: EXPERIMENTAL
Intervention: Catheter ablation and guideline-directed medical therapy
Number of subjects: 194

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 194